Invex TherapeuticsASX:IXC 37 OCF Yield % is -12.19 as of Jun. 25, 2026. GuruFocus rates ASX:IXC with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,419 Biotechnology companies, Invex Therapeutics ranks worse than 58.63% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Invex Therapeutics OCF Yield % Related Terms
Invex Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Invex Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IXC vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Invex Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invex Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invex Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Invex Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invex Therapeutics (ASX:IXC) has a OCF Yield % of -12.19 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Invex Therapeutics and its competitors. According to the industry distribution chart, Invex Therapeutics ranks #832 out of 1419 companies in the Biotechnology industry, placing it in the top 58.6%.
Is Invex Therapeutics' OCF Yield % too high?
Invex Therapeutics' current OCF Yield % is -12.19. Based on the distribution chart, Invex Therapeutics ranks #832 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Invex Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Invex Therapeutics ranks #832 out of 1419 companies for OCF Yield %. This places Invex Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current OCF Yield % is -12.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current OCF Yield % of -12.19. The current OCF Yield % is -12.19. Invex Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current OCF Yield % is -12.19 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
37GF Score
Get the complete analysis for ASX:IXC
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IXC has been successfully added to your 
